Thyrotropin receptor autoantibodies are independent risk factors for graves' ophthalmopathy and help to predict severity and outcome of the disease

被引:354
作者
Eckstein, Anja K.
Plicht, Marco
Lax, Hildegard
Neuhaeuser, Markus
Mann, Klaus
Lederbogen, Sebastian
Heckmann, Christian
Esser, Joachim
Morgenthaler, Nils G.
机构
[1] Essen Univ Clin, Dept Ophthalmol, Inst Med Informat Biometry & Epidemiol, D-45122 Essen, Germany
[2] Essen Univ Clin, Dept Med, Div Endocrinol, D-45122 Essen, Germany
[3] Univ Med Berlin, Inst Expt Endokrinol, D-10117 Berlin, Germany
[4] Univ Med Berlin, Endokrinol Forschungszentrum EnForCe, Charite, D-10117 Berlin, Germany
关键词
D O I
10.1210/jc.2005-2813
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: The objective of this study was to examine whether TSH-receptor antibody [TSH binding inhibitory antibodies (TBII)] levels are associated with the severity of Graves' ophthalmopathy (GO) over the entire course of the disease. Methods and Patients: A total of 159 patients with GO were followed for 12 - 24 months. One year after the first symptoms of GO, all patients were classified into mild or severe GO according to their clinical manifestations. TBII were measured every 3 months after onset of GO. Receiver operating characteristic plot analysis was performed to assess the power to discriminate both patient groups by TBII (specificity > 90%). Results: TBII levels and prevalence at each time point during follow-up were significantly higher in patients with a severe course of GO compared with patients with a mild course of GO. Prognostic statements on the course of the disease were possible for about half of the GO patients at all time points (except the first). If at first presentation and at consecutive time points TBII levels were less than 5.7, 2.6, 1.5, 1.5, 1.5, and 1.5 IU/liter, the patients had a 2.3- to 15.6-fold higher chance of a mild course. If 5 - 8 months after GO onset and at consecutive time points TBII levels were above 8.8, 5.1, 4.8, 2.8, and 2.8 IU/liter, the patients had a 8.7- to 31.1-fold higher risk of a severe course. This relationship of TBII to the severity was independent from age and smoking. Conclusion: Follow-up measurements of TBII allow, in half of the patients, assessment of the prognosis of GO and, therefore, could be of additional help for the disease management.
引用
收藏
页码:3464 / 3470
页数:7
相关论文
共 40 条
[1]   EFFECT OF RADIO-IODINE ON STIMULATORY ACTIVITY OF GRAVES IMMUNOGLOBULINS [J].
ATKINSON, S ;
MCGREGOR, AM ;
KENDALLTAYLOR, P ;
PETERSON, MM ;
SMITH, BR .
CLINICAL ENDOCRINOLOGY, 1982, 16 (06) :537-543
[2]   Pathophysiology of Graves' ophthalmopathy: The cycle of disease [J].
Bahn, RS .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2003, 88 (05) :1939-1946
[3]   Thyrotropin receptor expression in orbital adipose/connective tissues from patients with thyroid-associated ophthalmopathy [J].
Bahn, RS .
THYROID, 2002, 12 (03) :193-195
[4]   Thyrotropin receptor expression in Graves' orbital adipose/connective tissues: Potential autoantigen in Graves' ophthalmopathy [J].
Bahn, RS ;
Dutton, CM ;
Natt, N ;
Joba, W ;
Spitzweg, C ;
Heufelder, AE .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1998, 83 (03) :998-1002
[5]   Relationship between management of hyperthyroidism and course of the ophthalmopathy [J].
Bartalena, L ;
Tanda, ML ;
Piantanida, E ;
Lai, A ;
Pinchera, A .
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 2004, 27 (03) :288-294
[6]   Cigarette smoking and treatment outcomes in Graves ophthalmopathy [J].
Bartalena, L ;
Marcocci, C ;
Tanda, ML ;
Manetti, L ;
Dell'Unto, E ;
Bartolomei, MP ;
Nardi, M ;
Martino, E ;
Pinchera, A .
ANNALS OF INTERNAL MEDICINE, 1998, 129 (08) :632-635
[7]   Relation between therapy for hyperthyroidism and the course of Graves' ophthalmopathy [J].
Bartalena, L ;
Marcocci, C ;
Bogazzi, F ;
Manetti, L ;
Tanda, ML ;
Dell'Unto, E ;
Bruno-Bossio, G ;
Nardi, M ;
Bartolomei, MP ;
Lepri, A ;
Rossi, G ;
Martino, E ;
Pinchera, A .
NEW ENGLAND JOURNAL OF MEDICINE, 1998, 338 (02) :73-78
[8]   TSH BINDING-INHIBITING ANTIBODIES IN HYPERTHYROIDISM - RELATIONSHIP TO CLINICAL SIGNS AND HORMONE LEVELS [J].
BENKER, G ;
KOTULLA, P ;
KENDALLTAYLOR, P ;
EMRICH, D ;
REINWEIN, D .
CLINICAL ENDOCRINOLOGY, 1989, 30 (01) :19-28
[9]   GRAVES OPHTHALMOPATHY - CURRENT CONCEPTS REGARDING PATHOGENESIS AND MANAGEMENT [J].
BURCH, HB ;
WARTOFSKY, L .
ENDOCRINE REVIEWS, 1993, 14 (06) :747-793
[10]   Second generation assay for thyrotropin receptor antibodies has superior diagnostic sensitivity for Graves' disease [J].
Costagliola, S ;
Morgenthaler, NG ;
Hoermann, R ;
Badenhoop, K ;
Struck, J ;
Freitag, D ;
Poertl, S ;
Weglöhner, W ;
Hollidt, JM ;
Quadbeck, B ;
Dumont, JE ;
Schumm-Draeger, PM ;
Bergmann, A ;
Mann, K ;
Vassart, G ;
Usadel, KH .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1999, 84 (01) :90-97